How to Get Farxiga (Dapagliflozin) in North Dakota

What Farxiga Does and Why North Dakota Patients Seek It

Farxiga (dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubule of the kidney, causing excess glucose to be excreted in urine. The FDA first approved it for type 2 diabetes in 2014, then expanded approval to heart failure with reduced ejection fraction in 2020 and chronic kidney disease in 2021 1.

The clinical evidence behind these approvals is substantial. The DAPA-HF trial (N=4,744) showed that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74; 95% CI 0.65-0.85; P<0.001) in patients with heart failure and reduced ejection fraction, regardless of diabetes status 2. The DAPA-CKD trial (N=4,304) demonstrated a 39% reduction in the composite renal endpoint among patients with chronic kidney disease 3.

North Dakota has roughly 67,000 adults with diagnosed diabetes, according to CDC estimates 4. Access can be complicated by the state's rural geography, limited endocrinology specialists, and Medicaid formulary exclusions. This article maps every pathway to obtaining dapagliflozin in the state.

Telehealth Prescribing: The Fastest Route for Many ND Residents

Telehealth is legal and widely available for Farxiga prescriptions in North Dakota. The state does not require an in-person visit before a provider writes a prescription for an SGLT2 inhibitor.

North Dakota grants nurse practitioners full practice authority under NDCC 43-12.1, meaning NPs can independently evaluate, diagnose, and prescribe Farxiga without physician oversight 5. Physician assistants can prescribe under a collaborative agreement with a supervising physician. Any MD or DO with an active North Dakota medical license can prescribe via telehealth.

For patients in rural areas (Ward, Williams, McKenzie, and Mountrail counties, for example), telehealth eliminates drives that can exceed 100 miles to the nearest endocrinologist. A typical telehealth Farxiga visit takes 15 to 25 minutes and involves a review of recent lab work, medication history, and renal function. If labs are not current, the provider will order a basic metabolic panel and an eGFR before writing the prescription.

National platforms and HealthRX-affiliated providers offer same-day or next-day telehealth consultations for North Dakota residents. Prescriptions are sent electronically to any licensed pharmacy in the state.

Required Labs Before Starting Farxiga in North Dakota

Every prescriber in North Dakota will need baseline laboratory values before initiating dapagliflozin. This is not unique to the state. It is standard of care nationwide.

The American Diabetes Association's Standards of Care recommend checking eGFR before starting any SGLT2 inhibitor 6. Dapagliflozin is not recommended for initiation in patients with an eGFR below 25 mL/min/1.73 m² for the diabetes indication, though the heart failure indication allows use at lower eGFR values per FDA labeling 1.

Labs typically required include:

• Serum creatinine and eGFR to assess kidney function
• Fasting blood glucose and HbA1c to confirm glycemic baseline (for diabetes indication)
• Basic metabolic panel including potassium and bicarbonate
• Urinalysis to rule out active urinary tract infection
• Blood pressure measurement (SGLT2 inhibitors can lower systolic BP by 3 to 5 mmHg)

Lab draws can be completed at any LabCorp, Quest Diagnostics, or hospital-affiliated draw station across North Dakota. Bismarck, Fargo, Grand Forks, and Minot each have multiple locations. Results are usually available within 24 to 48 hours, and telehealth providers can review them electronically.

Follow-up monitoring should include repeat eGFR and electrolytes at 1 to 3 months after initiation, then every 6 to 12 months 6. An initial dip in eGFR of up to 10-15% is expected and typically stabilizes. The DAPA-CKD trial showed that this early eGFR decline was followed by a slower long-term rate of kidney function loss compared to placebo 3.

North Dakota Pharmacy Options for Farxiga

Once a prescription is written, patients in North Dakota can fill it at retail chain pharmacies, independent pharmacies, mail-order pharmacies, or licensed 503A compounding pharmacies.

Retail pharmacies. Walgreens, CVS (limited locations in ND), and local independents like Central Pharmacy in Fargo or City Drug in Williston can stock or order brand-name Farxiga. Stock availability varies. Rural pharmacies may need 2 to 3 business days to order the medication.

Mail-order pharmacies. Many insurance plans incentivize 90-day mail-order fills. Express Scripts, Optum Rx, and CVS Caremark all carry Farxiga. Delivery to North Dakota addresses typically takes 3 to 5 business days.

503A compounding pharmacies. North Dakota law permits licensed 503A pharmacies to compound dapagliflozin based on a patient-specific prescription. Compounded versions may cost less than the brand-name product for uninsured or underinsured patients. The North Dakota Board of Pharmacy oversees compounding standards and inspections 7.

A key consideration: generic dapagliflozin is not yet available in the United States as of mid-2026. AstraZeneca holds patent protections that are expected to extend into 2027. Patients without insurance coverage will face brand-name pricing.

North Dakota Medicaid Does Not Cover Farxiga

North Dakota Medicaid does not include Farxiga on its preferred drug list. This is a significant barrier. Patients enrolled in ND Medicaid who need an SGLT2 inhibitor should work with their prescriber to explore two options.

First, the prescriber can submit a prior authorization request to ND Medicaid arguing medical necessity. The Endocrine Society's 2024 clinical practice guideline recommends SGLT2 inhibitors as first-line add-on therapy for patients with type 2 diabetes and established cardiovascular disease or CKD 8. This recommendation, combined with individual patient data, can sometimes override formulary exclusions.

Second, patients can apply for the AstraZeneca patient assistance program (AZ&Me), which provides Farxiga at no cost to qualifying uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level 1.

Dr. Robert Eckel, past president of the American Heart Association, has stated: "SGLT2 inhibitors have redefined our treatment algorithms for type 2 diabetes by demonstrating benefits that extend well beyond glucose lowering, particularly in heart and kidney protection" 9.

The DECLARE-TIMI 58 trial (N=17,160) found that dapagliflozin reduced hospitalization for heart failure by 27% (HR 0.73; 95% CI 0.61-0.88) in patients with type 2 diabetes and multiple cardiovascular risk factors 10. Citing this data in a prior authorization letter strengthens the medical necessity argument.

Commercial Insurance and Prior Authorization in North Dakota

Most commercial plans in North Dakota (Blue Cross Blue Shield of North Dakota, Sanford Health Plan, Medica) do cover Farxiga but require prior authorization. The process works like this.

The prescriber's office submits a prior authorization form that includes the patient's diagnosis (ICD-10 code), HbA1c or eGFR values, a list of medications tried previously, and the clinical rationale for choosing dapagliflozin. Many plans require documentation that metformin was tried first (or is contraindicated) before approving an SGLT2 inhibitor for the diabetes indication. For heart failure or CKD indications, metformin step therapy is generally not required.

Turnaround time for prior authorization in North Dakota is typically 48 to 72 hours for standard requests. Urgent requests can be processed within 24 hours. If denied, patients have the right to appeal. The North Dakota Insurance Department oversees appeal timelines for fully insured plans 7.

Documentation checklist for prior authorization:

• Diagnosis with ICD-10 code (E11.9 for type 2 diabetes, I50.x for heart failure, N18.x for CKD)
• Current HbA1c (for diabetes indication)
• eGFR dated within the past 90 days
• Prior medication trial history (metformin, sulfonylureas, or DPP-4 inhibitors tried and failed or contraindicated)
• Prescriber letter of medical necessity citing guideline recommendations and trial data

The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor with proven benefit is recommended independent of HbA1c" 6. Quoting this directly in the prior authorization letter is effective.

Cost Without Insurance in North Dakota

Brand-name Farxiga carries a wholesale acquisition cost of approximately $550 to $600 for a 30-day supply of 10 mg tablets. Cash prices at North Dakota pharmacies range from $500 to $620 depending on the pharmacy.

Several strategies can reduce out-of-pocket cost:

AstraZeneca Savings Card. Commercially insured patients may be eligible for a copay card that reduces the monthly cost to as low as $0. The maximum annual benefit is typically $3,400. This card does not apply to government insurance (Medicare, Medicaid, Tricare, VA).

GoodRx or RxSaver coupons. These discount platforms sometimes reduce the cash price to $430 to $480 at participating North Dakota pharmacies.

503A compounding. A compounded dapagliflozin preparation from a licensed North Dakota 503A pharmacy may cost $80 to $200 per month, depending on the pharmacy and preparation.

AZ&Me patient assistance. For qualifying uninsured patients, AstraZeneca provides Farxiga free of charge.

Medicare Part D. Medicare patients should check their specific plan formulary. Under the Inflation Reduction Act, out-of-pocket prescription drug costs for Medicare Part D enrollees are capped at $2,000 per year as of 2025 11.

Transferring a Farxiga Prescription to North Dakota

Patients relocating to North Dakota from another state can transfer an existing Farxiga prescription. The process is straightforward.

Call the new North Dakota pharmacy and provide the name and phone number of the out-of-state pharmacy currently holding the prescription. The North Dakota pharmacist will contact the originating pharmacy to transfer remaining refills. North Dakota accepts prescription transfers from all 50 states for Schedule V and non-controlled medications. Farxiga is not a controlled substance, so no additional DEA documentation is required.

If the prescription has no remaining refills, the patient will need to establish care with a North Dakota-licensed prescriber. A telehealth visit is the fastest option. Bring previous lab results and medication records to the appointment.

One caveat: prior authorization does not transfer between insurance plans. If the patient switches insurance as part of a relocation, a new prior authorization may be needed with the new plan.

Who Can Prescribe Farxiga in North Dakota

North Dakota allows three categories of prescribers to write Farxiga prescriptions.

Physicians (MD and DO). Any physician with an active North Dakota medical license can prescribe dapagliflozin. This includes primary care physicians, endocrinologists, cardiologists, and nephrologists.

Nurse Practitioners (NP). North Dakota is a full practice authority state for NPs. Certified NPs with prescriptive authority can independently prescribe Farxiga without a collaborating physician 5. This is particularly relevant in rural North Dakota, where NPs serve as primary care providers in many communities.

Physician Assistants (PA). PAs in North Dakota can prescribe under a collaborative agreement with a supervising physician. The PA's prescriptive authority must include non-controlled prescription drugs.

Specialists are not required for a Farxiga prescription. A primary care provider can initiate and manage dapagliflozin for any of its three FDA-approved indications. The KDIGO 2024 guideline recommends that primary care providers prescribe SGLT2 inhibitors for eligible CKD patients rather than waiting for nephrology referral 12.

Safety Monitoring and Side Effects Specific to North Dakota Patients

Farxiga's most common side effects include genital mycotic infections (affecting roughly 5-7% of women and 2-3% of men), urinary tract infections, and volume depletion 1. North Dakota's dry continental climate during winter months (November through March) may increase dehydration risk for patients on dapagliflozin, particularly older adults.

Diabetic ketoacidosis (DKA) is a rare but serious risk. The FDA requires a boxed warning. Patients should be counseled to stop dapagliflozin at least 3 days before scheduled surgery and to watch for DKA symptoms (nausea, vomiting, abdominal pain, fatigue) during illness or fasting 1. The DAPA-HF trial reported DKA in 0.1% of the dapagliflozin group versus 0% in the placebo group 2.

Fournier's gangrene (necrotizing fasciitis of the perineum) has been reported in post-marketing surveillance, though incidence is extremely low. The FDA issued a safety communication in 2018 regarding this risk with all SGLT2 inhibitors 13.

Patients on diuretics should have volume status monitored closely. Dapagliflozin has an additive diuretic effect, and symptomatic hypotension may occur, especially in the first two weeks of therapy.

Timeline: From First Visit to First Dose in North Dakota

Getting Farxiga in North Dakota follows a predictable timeline for most patients.

• Day 1. Schedule a telehealth or in-person visit. If labs are current (within 90 days), the provider may prescribe at the first visit.
• Days 1-3. If labs are needed, complete a blood draw at a local lab. Results return in 24-48 hours.
• Days 2-4. Provider reviews labs and sends the electronic prescription to the patient's pharmacy of choice.
• Days 2-7. Prior authorization is submitted (if required by insurance). Standard turnaround is 48-72 hours.
• Days 3-10. Pharmacy fills the prescription. Retail pharmacies that stock Farxiga can fill same-day. Rural pharmacies may need to order it (1-3 additional days). Mail-order pharmacies ship within 3-5 business days.

Total time from first appointment to first dose: 3 to 10 business days for most patients. Patients with current labs and no prior authorization requirement can receive Farxiga within 1 to 2 days.